Research Article

Survival and desferrioxamine in thalassaemia major.

Br Med J (Clin Res Ed) 1982; 284 doi: (Published 10 April 1982) Cite this as: Br Med J (Clin Res Ed) 1982;284:1081
  1. B Modell,
  2. E A Letsky,
  3. D M Flynn,
  4. R Peto,
  5. D J Weatherall


    A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.